News
Comphya receives approval for first pilot clinical trial in Australia
02 March 2023PRESS RELEASE Lausanne, Switzerland, March 2nd, 2023. Comphya SA, developer of the first neuromodulator to treat erectile dysfunction (ED), announced today that Australian regulatory authorities...
Read more
Comphya successfully raises additional funds for pilot clinical trials
31 January 2023PRESS RELEASE Lausanne, Switzerland, January 31st, 2023. Comphya SA, developer of the first neuromodulator to treat erectile dysfunction (ED), today announced the fundraising of CHF...
Read more
Comphya adds top clinicians as advisors
29 September 2022PRESS RELEASE A pioneer in robotic surgery and two leading authorities in men’s sexual health join Comphya’s Clinical Advisory Board. This gives the startup a...
Read more
Low-intensity electrostimulation reestablishes erectile function after prostatectomy
16 March 2022PRESS RELEASE A study published in the Journal of Sexual Medicine shows that Comphya’s implantable neurostimulator does not only allow on-demand penile erection, but could...
Read more
Comphya announces that two new patents have been granted in the U.S. for the CaverSTIM system
02 December 2021PRESS RELEASE Lausanne, Switzerland, December 02nd, 2021. Comphya SA, a medical device company focusing on the treatment of erectile dysfunction by neuromodulation for non-responders to...
Read more
Comphya has received ISO 13485 certification for the design, development, manufacture and sterilization
28 October 2021PRESS RELEASE Lausanne, Switzerland, October 28th, 2021. Comphya announces that it has received the ISO 13485 certificate for Medical Device and Quality Management Systems. The...
Read more
Comphya strengthens its team with the appointment of Pierre Chauvineau as new Board of Director
10 February 2021PRESS RELEASE Lausanne, Switzerland, February 10th, 2021. Comphya SA, the developer of CaverSTIM, the first implantable neurostimulator to restore erectile function in non-responders to oral...
Read more
Comphya raises additional USD 1.3 million to secure the execution of the pilot clinical trials to start early 2021
01 December 2020PRESS RELEASE Lausanne, Switzerland, December 01st, 2020. Comphya SA, a developer of the first neuromodulator to treat erectile dysfunction, today announced the fundraising of USD...
Read more
CaverSTIM system is now powered by ACCEL+ IPG platform.
21 October 2020PRESS RELEASE Lausanne, Switzerland, October 21th, 2020. Comphya SA, the developer of CaverSTIM, and Cirtec Medical Corp. today announced their decision to transfer the development...
Read more
Comphya appoints Mikael Sturny as Chief Technology Officer.
02 October 2020PRESS RELEASE Lausanne, Switzerland, September 22, 2020 - Comphya SA, the developer of CaverSTIM, announced today the appointment of Mikael Sturny as Chief Technology Officer....
Read more